A detailed history of Channing Capital Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Channing Capital Management, LLC holds 55,401 shares of ABBV stock, worth $9.97 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
55,401
Previous 58,312 4.99%
Holding current value
$9.97 Million
Previous $10 Million 9.39%
% of portfolio
0.29%
Previous 0.28%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $476,938 - $580,249
-2,911 Reduced 4.99%
55,401 $10.9 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $901,806 - $1.05 Million
5,826 Added 11.1%
58,312 $10 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $1.04 Million - $1.18 Million
-6,500 Reduced 11.02%
52,486 $9.56 Million
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $433,715 - $488,465
3,152 Added 5.65%
58,986 $9.14 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $912,553 - $1.06 Million
-6,831 Reduced 10.9%
55,834 $8.32 Million
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $1.22 Million - $1.52 Million
9,218 Added 17.25%
62,665 $8.44 Million
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $2.31 Million - $2.66 Million
-15,984 Reduced 23.02%
53,447 $8.52 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $9.6 Million - $11.5 Million
69,431 New
69,431 $11.2 Million
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $4.83 Million - $5.69 Million
-62,619 Closed
0 $0
Q4 2018

Feb 12, 2019

SELL
$77.85 - $96.01 $2.08 Million - $2.57 Million
-26,719 Reduced 29.91%
62,619 $5.77 Million
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $2.28 Million - $2.54 Million
25,686 Added 40.35%
89,338 $8.45 Million
Q2 2018

Jul 20, 2018

BUY
$89.78 - $106.23 $5.71 Million - $6.76 Million
63,652 New
63,652 $5.9 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Channing Capital Management, LLC Portfolio

Follow Channing Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Channing Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Channing Capital Management, LLC with notifications on news.